BioSpace News Archive

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced a corporate summary for the fiscal year ended December 31, 2022.

Everest Medicines announced its strategic plans for the next two years and beyond as the Company progresses to becoming a fully-integrated biopharmaceutical company with expertise and capabilities across the full biotechnology value chain, including proven self-discovery and in-licensing, clinical development, and established manufacturing and commercialization.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. PT in San Francisco, CA.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that its first clinical trial site has been contracted and that first dosing of patients is expected in early 2023.

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, announced that the company is presenting at Biotech Showcase™ 2023.

Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland today announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma’s Flector® (diclofenac epolamine) topical system.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID® (pimavanserin) compared to other atypical antipsychotics over 12 months and across various subgroups.

DexCom, Inc. announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023.

JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic solid tumors with confirmed BRAF V600E/K mutations (NCT04418167).

Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, will showcase TempTraq® at the 2023 Consumer Electronics Show at the Las Vegas Convention Center January 5-8.